Fig. 4 | Bone Research

Fig. 4

From: Iron homeostasis and ferroptosis in muscle diseases and disorders: mechanisms and therapeutic prospects

Fig. 4

Strategies for targeting ferroptosis in treating muscle diseases and disorders. Dysregulated iron metabolism, lipid peroxidation, oxidation, and antioxidant imbalances have all been implicated in the development of a variety of diseases and disorders affecting muscles. These muscle diseases and disorders can be treated using either inhibitors (anti-ferroptosis strategies) or inducers (pro-ferroptosis strategies). This figure was created with BioRender (https://biorender.com/). Abbreviations: 4-HNE 4-hydroxynonaldehyde, ACSL4 acyl-CoA synthetase long-chain family member 4, DFO deferoxamine, DFP Deferiprone, Fer-1 ferrostatin-1, FSP1 ferroptosis suppressor protein 1, FTH ferritin heavy chain, GPX4 glutathione peroxidase 4, GSH glutathione, HO-1 heme oxygenase-1,IRP1/2 iron-regulated protein 1/2, Lip-1 liproxstatin-1, MDA malondialdehyde, NAC N-acetylcysteine, Nrf2 nuclear factor erythroid 2-related factor 2, PTGS2 prostaglandin-endoperoxide synthase 2, ROS reactive oxygen species, SLC7A11 solute carrier family 7 member 11, SLC39A14 metal cation symporter ZIP14, SOD superoxide dismutase, TfR1 transferrin receptor protein 1

Back to article page